Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07087002 · ClinicalTrials.gov registry record · Phase 1
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
A Phase 1 study of Medulloblastoma and Recurrent Medulloblastoma, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT07087002 is a Phase 1 study of Medulloblastoma and Recurrent Medulloblastoma that is actively recruiting participants, run by Stanford University. The registered enrollment target is 18 participants, below the 140-participant average among 29 other Medulloblastoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07087002, a Phase 1 study of Medulloblastoma and Recurrent Medulloblastoma, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-site, open-label Phase 1 clinical trial evaluating the feasibility, safety, and preliminary activity of autologous GPC2-targeted chimeric antigen receptor (CAR) T cells administered via intracerebroventricular (ICV) infusion in children and young adults with relapsed or refractory medulloblastoma or other eligible Central Nervous System (CNS) embryonal tumors.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL GPC2-CAR T cells
Study Locations (1)
California
- Lucile Packard Children's Hospital Stanford - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-08-28 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07087002
The ClinicalTrials.gov registry entry for NCT07087002 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 29 other Medulloblastoma trials with a reported enrollment target (87% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Medulloblastoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT07087002 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07087002 about?
NCT07087002 is a clinical study titled "GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults". This is a single-site, open-label Phase 1 clinical trial evaluating the feasibility, safety, and preliminary activity of autologous GPC2-targeted chimeric antigen receptor (CAR) T cells administered via intracerebroventricular (ICV) infusion in children and young adults with relapsed or refractory m...
What is the current status of trial NCT07087002?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-08-28. Estimated completion is 2027-08.
What conditions does trial NCT07087002 study?
This clinical trial studies the following conditions: Medulloblastoma, Recurrent Medulloblastoma, Pediatric Brain Tumor, Pineoblastoma, Refractory Medulloblastoma.
What interventions are being tested in trial NCT07087002?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), GPC2-CAR T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT07087002?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07087002 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medulloblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
RECRUITING · Phase 1
-
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RECRUITING · Phase 1
-
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
RECRUITING · Phase 1
-
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
RECRUITING · Phase 1
-
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
RECRUITING · Phase 1
-
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.